Pharma BD Deal Intelligence
BioImagene products will complement and strengthen our current offering in image analysis and information management. - Daniel O'Day, COO Roche Diagnostics.…
Acquisition gives Ventana an end-to-end digital workflow (Virtuoso, iScan, Companion Algorithms, iSlide, Crescendo) layered onto its VIAS market-leading IHC…
Roche framed the deal as strengthening cancer diagnostics, with COO Daniel O'Day citing the 'tremendous need for more sophisticated tools for tissue analysis…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Ventana Medical Systems (Roche Group) acquired BioImagene for ~$100M, giving Roche entry into digital pathology workflow and analysis market.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / BioImagene, Inc. (this deal) | 2010 | $100M | 55 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2010 deals · Roche Holding AG deals · Other deals